The Drug Safety Research Unit (DSRU) is a leading Unit in the field of pharmacoepidemiology and pharmacovigilance with expertise in handling data at national level. The DSRU is well-known for conducting Prescription-Event Monitoring studies on prescriptions data from general practitioners in England, including studies on anti-diabetics, rosiglitazone, pioglitazone, nateglinide and repaglinide. However, the Unit also conducts and collaborates in a variety of other drug safety projects, including a study of the spontaneous reporting of adverse drug reactions, the Drug-Induced Arrhythmia Risk Evaluation study (DARE) study, Hospital-Event Monitoring studies on drugs for mental health disorders, and the FP7-funded ARITMO project.
In SAFEGUARD DSRU will participate as Work Package Leader of WP3 and will collaborate in WP5.
- Saad Shakir
- Lorna Hazell
- Miranda Davies
- Deborah Layton
- Shane Kelly
- Vicki Osborne
Contact email: email@example.com